UPDATE: Canaccord Genuity Upgrades AEterna Zentaris (AEZS) to Spec. Buy; Analyst Notes Removal of Dilution Overhang From Series B Warrants

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to UPDATE: Canaccord Genuity Upgrades AEterna Zentaris (AEZS) to Spec. Buy; Analyst Notes Removal of Dilution Overhang From Series B Warrants

Aeterna Zentaris Reports Third Quarter Financial and Operating Results

November 5, 2015 5:00 PM EST

Strong fundamentals; dilution from Series B Warrants substantially ended

All amounts are in US Dollars

Third quarter key developments

Saizen® promotional activities show early promise EstroGel® year-over-year new-prescription growth continues ahead of the market in the Company's territories Zoptrex (zoptarelin doxorubicin) receives DSMB recommendation to continue ZoptEC Phase 3 clinical program to completion following review of the final interim efficacy and safety data (after quarter end) Zoptrex meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration- and Taxane-Resistant Prostate... More